Lantheus and POINT Biopharma Announce Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

12/18/23 7:31:51 AM ET

$LNTH

$PNT

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LNTH alert in real time by email

Lantheus Holdings, Inc. (Lantheus) (NASDAQ:LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ:PNT) today announced statistically significant topline results from the pivotal Phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor (ARPI).

Get the next $LNTH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LNTH
$PNT

Company	Date	Price Target	Rating	Analyst
Lantheus Holdings Inc. $LNTH	9/3/2024	$175.00	Buy	Redburn Atlantic
Lantheus Holdings Inc. $LNTH	7/10/2024	$100.00 → $130.00	Mkt Outperform	JMP Securities
Lantheus Holdings Inc. $LNTH	12/18/2023		Outperform → Mkt Perform	William Blair
Lantheus Holdings Inc. $LNTH	12/4/2023	$100.00	Outperform	TD Cowen
Lantheus Holdings Inc. $LNTH	9/29/2023		Outperform	William Blair
POINT Biopharma Global Inc. $PNT	7/20/2023	$12.00 → $14.00	Buy	Jefferies
Lantheus Holdings Inc. $LNTH	3/8/2023	$120.00	Mkt Outperform	JMP Securities
POINT Biopharma Global Inc. $PNT	12/14/2022	$10.00	Outperform	Raymond James

More analyst ratings

$LNTH
$PNT
Press Releases

Fastest customizable press release news feed in the world

Lantheus Announces Share Repurchase Program
BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announces that its board of directors has authorized a program to repurchase up to $250 million of its common stock during the next twelve months. "With our strong financial position and the Board's commitment to shareholder value, this share repurchase program reflects our confidence in Lantheus' continued radiopharmaceuticals leadership and ability to drive long-term, sustainable growth," said Brian Markison, Chief Executive
11/20/24 1:00:00 AM ET
$LNTH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Lantheus to Present at the Jefferies London Healthcare Conference
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 1:00 p.m. GMT (8 a.m. EST) on Wednesday, November 20. To access a live webcast of the presentation, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcast will be available on the Company's website for at least 30 days following the live presentation. About Lant
11/13/24 8:30:00 AM ET
$LNTH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025
BEDFORD, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, notes that the Centers for Medicare & Medicaid Services (CMS) recently posted updated payment rates in Addendum B related to the final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The Company continues to commend CMS for recognizing the value of and ensuring broad patient access to specialized diagnostic radiopharmaceuticals. With PYLARIFY® (piflufolastat F 18) on track to e
11/11/24 7:39:54 AM ET
$LNTH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

Lantheus Reports Third Quarter 2024 Financial Results
Worldwide revenue of $378.7 million, an increase of 18.4% from third quarter 2023GAAP fully diluted earnings per share of $1.79, compared to $1.88 in the third quarter of 2023. Adjusted fully diluted earnings per share of $1.70 compared to $1.47 in the third quarter of 2023Company narrows full year 2024 revenue and fully diluted earnings per share guidance towards higher end of the previously issued guidanceCompany applauds CMS' CY25 rule to improve payment for specialized diagnostic radiopharmaceuticals, including PYLARIFY, advancing patient access and careCompany announced that it expanded its Alzheimer's disease radiodiagnostics portfolio with NAV-4694, a novel, next generation late-stage
11/6/24 7:00:00 AM ET
$LNTH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time
BEDFORD, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2024, to discuss its financial and operating results for the third quarter of 2024. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days. About
10/23/24 8:30:00 AM ET
$LNTH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Lantheus Reports Second Quarter 2024 Financial Results
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023Completed three strategic transactions to expand innovative pipelineGAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.54 in the second quarter 2023, reflective of inter-quarter investment in business development and R&D.The Company maintains full year 2024 revenue guidance and updates fully diluted earnings per share guidance driven by strategic transactions BEDFORD, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ:LNTH), the
7/31/24 7:00:00 AM ET
$LNTH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

Lantheus Appoints Julie Eastland as New Board Member
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors ("Board"), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent. "We are thrilled to welcome Julie Eastland t
9/5/24 8:30:00 AM ET
$DVAX
$LNTH
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Lantheus Appoints Jamie Spaeth as Chief People Officer
BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Jamie Spaeth to its Executive Team as Chief People Officer. "We're excited to have Jamie join Lantheus as we continue to harness our team's potential to deliver innovative solutions to serve patients and healthcare professionals," said Dan Niedzwiecki, Chief Administrative Officer of Lantheus. "At Lantheus, our people drive our success, and Jamie's proven leadership and expertise will foster a collaborativ
7/8/24 8:30:00 AM ET
$LNTH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors
Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa
5/28/24 9:30:00 AM ET
$ACHV
$ALGS
$DCTH
$PNT
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments

Lantheus and POINT Biopharma Announce Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

Chat with this insight

Recent Analyst Ratings for $LNTH$PNT

$LNTH$PNT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CFO and Treasurer Marshall Robert J. Jr. sold $812,000 worth of shares (10,000 units at $81.20), decreasing direct ownership by 9% to 102,963 units (SEC Form 4)

President Blanchfield Paul sold $159,300 worth of shares (2,000 units at $79.65) and gifted 355 shares, decreasing direct ownership by 2% to 96,737 units (SEC Form 4)

Director Heino Mary Anne sold $1,001,218 worth of shares (11,487 units at $87.16), decreasing direct ownership by 3% to 443,436 units (SEC Form 4)

$LNTH$PNT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Redburn Atlantic initiated coverage on Lantheus Holdings with a new price target

JMP Securities reiterated coverage on Lantheus Holdings with a new price target

Lantheus Holdings downgraded by William Blair

$LNTH$PNT Press Releases

Fastest customizable press release news feed in the world

Lantheus Announces Share Repurchase Program

Lantheus to Present at the Jefferies London Healthcare Conference

Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025

$LNTH$PNT Financials

Live finance-specific insights

$LNTH$PNT Leadership Updates

Live Leadership Updates

$LNTH$PNT Market Insights

Live Market Insights

$LNTH$PNT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Lantheus Reports Third Quarter 2024 Financial Results

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time

Lantheus Reports Second Quarter 2024 Financial Results

Lantheus Appoints Julie Eastland as New Board Member

Lantheus Appoints Jamie Spaeth as Chief People Officer

Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

Jones Trading Maintains Buy on Lantheus Holdings, Raises Price Target to $137

Russell 2000 Marks Fifth Day Of Gains: What's Driving Surge In Small-Cap Stocks?

Lantheus Acquires Meilleur Technologies, Including The NAV-4694 ß Amyloid PET Imaging Agent For Alzheimer's Disease; Financial Terms Not Disclosed

SEC Form SC 13G filed by Lantheus Holdings Inc.

Amendment: SEC Form SC 13G/A filed by Lantheus Holdings Inc.

SEC Form SC 13G filed by Lantheus Holdings Inc.

$LNTH$PNT SEC Filings

SEC Form 8-K filed by Lantheus Holdings Inc.

SEC Form 144 filed by Lantheus Holdings Inc.

SEC Form 10-Q filed by Lantheus Holdings Inc.

$LNTH$PNT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Lantheus Alpha Therapy, Llc bought $57,409,487 worth of shares (60,431,039 units at $0.95) (SEC Form 4)

Recent Analyst Ratings for
$LNTH
$PNT

$LNTH
$PNT
Insider Trading

$LNTH
$PNT
Analyst Ratings

$LNTH
$PNT
Press Releases

$LNTH
$PNT
Financials

$LNTH
$PNT
Leadership Updates

$LNTH
$PNT
Market Insights

$LNTH
$PNT
Large Ownership Changes

$LNTH
$PNT
SEC Filings

$LNTH
$PNT
Insider Purchases